
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:21073</ns1:identifier>
    <ns1:title language="sr">Primena multikriterijumskie optimizacije i koncepta dizanja kvaliteta u razvoju metoda tečne hromatografije pod ultravisonim pritiskom i micelarne tečne hromatografije za praćenje stabilnosti cilazaprila i hidrohlorotiazida</ns1:title>
    <ns2:subtitle language="sr">doktorska disertacija</ns2:subtitle>
    <ns2:alt_title language="en">Multicriteria optimization and Quality by Design concept in development of ultrahigh pressure liquid chromatographic and micellar liquid chromatographic methods for investigation of cilazapril and hidrochlorothiazide stability : doctoral dissertation</ns2:alt_title>
    <ns1:language>sr</ns1:language>
    <ns1:description language="sr">Cilazapril je potentan dugodjelujući inhibitor angiotenzin-konvertirajućeg
enzima. On je prolijek cilazaprilata koji je ujedno i njegov aktivni metabolit.
Hidrohlorotiazid je tiazidni diuretik koji inhibira reapsorpciju natrija i hlorida iz
bubrežnih tubula i istovremeno povećava izlučivanje kalija. Cilazapril i hidrohlorotiazid
se koriste kao monoterapija, ali i u kombinaciji pri čemu pokazuju sinergistički
antihipertenzivni efekat.
Procjena efikasnosti, kvaliteta i bezbijednosti farmaceutskog doziranog oblika
podrazumijeva ispitivanje njegove hemijske stabilnosti pri različitim uslovima čuvanja.
Ovo se prvenstveno odnosi na stabilnost aktivnih farmaceutskih supstanci koja ovisi o
hemijskoj strukturi, a ispituje se sprovođenjem studija forsirane degradacije. Cilj studija
forsirane degradacije je praćenje degradacionih proizvoda, utvrđivanje puteva njihovog
nastanka i razvoj stability-indicating metode.
Simultano razdvajanje cilazaprila, hidrohlorotiazida i njihovih degradacionih
proizvoda u toku jedne hromatografske analize za što kraće vrijeme je veoma zahtjevan
zadatak jer se ispitivani analiti značajno razlikuju po lipofilnosti i apsorpcionim
karakteristikama. Složenost ispitivanog sistema je zahtijevala primjenu metodologije
multikriterijumskog odlučivanja korištenjem centralnog kompozicionog dizajna i
Derringer-ove funkcije poželjnih odgovora. Razvijena je gradijentna stabilityindicating
RP UHPLC metoda za razdvajanje cilazaprila, hidrohlorotiazida i njihovih
degradacionih proizvoda. Validacija optimizovane RP HPLC metode je izvršena u cilju
potvrde njene primjenljivosti u rutinskim analizama...</ns1:description>
    <ns1:description language="en">Cilazapril is a potent long-acting angiotensin-converting enzyme inhibitor. It is a
prodrug of cilazaprilat which is also its active metabolite. Hydrochlorothiazide is a
thiazide diuretic which inhibits sodium and chloride reabsorption from kidney tubules
and simultaneously increases potassium secretion. Cilazapril and hydrochlorothiazide
are used as monotherapy, but also in combination, showing a synergistic
antihypertensive effect.
The evaluation of efficiency, quality and safety of the pharmaceutical dosage
form implies an investigation of its chemical stability under various storage conditions.
This primarily relates to the stability of active pharmaceutical substances that depend on
the chemical structure which is tested by conducting a forced degradation study. The
aim of the forced degradation studies is the monitoring of degradation products,
establishment of the paths of their formation and the development of stability-indicating
method.
Simultaneous separation of cilazapril, hydrochlorothiazide and their degradation
products during one chromatographic analysis for a shorter time is a very demanding
task because the analyzed analytes differ significantly by lipophilicity and absorption
characteristics. The complexity of the investigated system required the application of
multicriteria decision-making methodology using central composite design and
Derringer&apos;s desirable responses function. A gradient stability-indicating RP UHPLC
method was developed for the separation of cilazapril, hydrochlorothiazide and their
degradation products. The validation of the optimized RP HPLC method was performed
to confirm its applicability in routine analyzes...</ns1:description>
    <ns1:description language="sr">Farmacija - Analitika lekova / Pharmacy- Drug analysis  
Datum odbrane: 11.10.2019. </ns1:description>
    <ns1:keyword language="sr">cilazapril, hidrohlorotiazid, stability-indicating metoda, gradijentnaUHPLC, izokratska micelarna HPLC, multikriterijumska optimizacija, pretraga čvorovamreže, AQbD, indirektno modelovanje, testiranje robusnosti</ns1:keyword>
    <ns1:keyword language="en">cilazapril, hydrochlorothiazide, stability-indicating method, gradientUHPLC, isocratic micellar HPLC, multicriteria optimization, grid point search, AQbD,indirect modeling, robustness testing</ns1:keyword>
    <ns1:keyword language="sr">615.225:543.544.068.7(043.3)</ns1:keyword>
    <ns2:irdata>yes</ns2:irdata>
    <ns2:identifiers>
      <ns2:identifier>2048398434</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552101</ns2:resource>
      <ns2:identifier>7295</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552100</ns2:resource>
      <ns2:identifier>2048398434</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2020-02-26T10:20:52.053Z</ns1:upload_date>
    <ns1:status>45</ns1:status>
    <ns2:peer_reviewed>no</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Jasmina, 1986-, 28253031</ns3:firstname>
        <ns3:lastname>Šljivić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2019</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="1">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Mira, 1963-, 12648039</ns3:firstname>
        <ns3:lastname>Zečević</ns3:lastname>
      </ns1:entity>
      <ns1:date>2019</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="2">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Biljana, 1977-, 16886887</ns3:firstname>
        <ns3:lastname>Otašević</ns3:lastname>
      </ns1:entity>
      <ns1:date>2019</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="3">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Ana, 1979-, 13846119</ns3:firstname>
        <ns3:lastname>Protić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2019</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="4">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Anđelija, 1971-, 12822631</ns3:firstname>
        <ns3:lastname>Malenović</ns3:lastname>
      </ns1:entity>
      <ns1:date>2019</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="5">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Alija, 28256103</ns3:firstname>
        <ns3:lastname>Uzunović</ns3:lastname>
      </ns1:entity>
      <ns1:date>2019</ns1:date>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>147 listova</ns1:format>
    <ns1:size>7216130</ns1:size>
    <ns1:location>http://phaidrabg.bg.ac.rs/o:21073</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>4</ns1:license>
  </ns1:rights>
  <ns1:annotation>
    <ns6:annotations>
      <ns6:date>2020-02-26T10:20:52.320Z</ns6:date>
    </ns6:annotations>
  </ns1:annotation>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
    <ns7:taxonpath>
      <ns7:source>11</ns7:source>
      <ns7:taxon seq="0">1067094</ns7:taxon>
      <ns7:taxon seq="1">1067101</ns7:taxon>
    </ns7:taxonpath>
    <ns7:keyword language="sr" seq="0">cilazapril, hidrohlorotiazid, stability-indicating metoda, gradijentnaUHPLC, izokratska micelarna HPLC, multikriterijumska optimizacija, pretraga čvorovamreže, AQbD, indirektno modelovanje, testiranje robusnosti</ns7:keyword>
    <ns7:keyword language="en" seq="1">cilazapril, hydrochlorothiazide, stability-indicating method, gradientUHPLC, isocratic micellar HPLC, multicriteria optimization, grid point search, AQbD,indirect modeling, robustness testing</ns7:keyword>
    <ns7:keyword language="sr" seq="2">615.225:543.544.068.7(043.3)</ns7:keyword>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>1738</ns8:hoschtyp>
    <ns8:orgassignment>
      <ns8:faculty>11A13</ns8:faculty>
    </ns8:orgassignment>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:releaseyear>2019</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>
